ATE544452T1 - Pharmazeutisch aktive isoindolin-derivate - Google Patents

Pharmazeutisch aktive isoindolin-derivate

Info

Publication number: ATE544452T1
Authority: AT; Austria
Prior art keywords: pharmaceutically active; isoindoline derivatives; active isoindoline; derivatives; oxoisoindoline
Prior art date: 1999-11-12

Application number

AT10176420T

Other languages

English (en)

Inventor

Hon-Wah Man

George W Muller

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-12

Filing date

2000-11-09

Publication date

2012-02-15

2000-11-09 Application filed by Celgene Corp filed Critical Celgene Corp

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE544452T1 publication Critical patent/ATE544452T1/de

Links

GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical class C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 title 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
QDZOBXFRIVOQBR-LJQANCHMSA-N n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3-oxo-1h-isoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2)=O)=C1 QDZOBXFRIVOQBR-LJQANCHMSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Virology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Biotechnology (AREA)
Orthopedic Medicine & Surgery (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT10176420T 1999-11-12 2000-11-09 Pharmazeutisch aktive isoindolin-derivate ATE544452T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16516899P	1999-11-12	1999-11-12
US59034400A	2000-06-08	2000-06-08
US09/708,199 US6667316B1 (en)	1999-11-12	2000-11-08	Pharmaceutically active isoindoline derivatives

Publications (1)

Publication Number	Publication Date
ATE544452T1 true ATE544452T1 (de)	2012-02-15

Family

ID=27389110

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
AT06009632T ATE506058T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch aktive isoindolin-derivate
AT10176390T ATE544451T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch aktive isoindolin-derivate
AT10176420T ATE544452T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch aktive isoindolin-derivate
AT00977095T ATE357913T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch-aktive isoindolin-derivate

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
AT06009632T ATE506058T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch aktive isoindolin-derivate
AT10176390T ATE544451T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch aktive isoindolin-derivate

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT00977095T ATE357913T1 (de)	1999-11-12	2000-11-09	Pharmazeutisch-aktive isoindolin-derivate

Country Status (19)

Country	Link
US (1)	US6667316B1 (de)
EP (4)	EP2255801B1 (de)
JP (1)	JP5116201B2 (de)
CN (1)	CN1325497C (de)
AT (4)	ATE506058T1 (de)
AU (2)	AU782409B2 (de)
CA (1)	CA2392081C (de)
CY (2)	CY1107610T1 (de)
DE (1)	DE60034139T2 (de)
DK (2)	DK2263669T3 (de)
ES (4)	ES2380574T3 (de)
FI (1)	FI119931B (de)
HK (1)	HK1049158A1 (de)
MX (1)	MXPA02004793A (de)
NO (2)	NO323633B1 (de)
NZ (1)	NZ519459A (de)
PT (2)	PT1228071E (de)
SI (1)	SI1228071T1 (de)
WO (1)	WO2001034606A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6429221B1 (en)	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
US6518281B2 (en) *	1995-08-29	2003-02-11	Celgene Corporation	Immunotherapeutic agents
ES2315435T3 (es) *	1996-08-12	2009-04-01	Celgene Corporation	Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
US8030343B2 (en) *	2000-06-08	2011-10-04	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US7491634B2 (en) *	2006-04-28	2009-02-17	Asm International N.V.	Methods for forming roughened surfaces and applications thereof
CA2444704C (en)	2001-04-23	2012-07-10	University Of Virginia Patent Foundation	Synthesis and evaluation of phthalimide mimics as anti-angiogenic agents
WO2003014315A2 (en) *	2001-08-06	2003-02-20	The Children's Medical Center Corporation	Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US8263637B2 (en) *	2002-05-17	2012-09-11	Celgene Corporation	Methods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide
US7842691B2 (en)	2002-10-15	2010-11-30	Celgene Corporation	Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
US20040087558A1 (en)	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) *	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
EP1567148A4 (de) *	2002-10-31	2010-09-15	Celgene Corp	Verfahren zur verwendung von undzusammensetzungen mit selektiven zytokin-hemmern zur behandlung undversorgung von makuladegeneration
US7776907B2 (en) *	2002-10-31	2010-08-17	Celgene Corporation	Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
BR0316002A (pt) *	2002-11-06	2005-09-13	Celgene Corp	Métodos de tratar ou prevenir e controlar uma doença mieloproliferativa, de reduzir ou evitar de um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica e kit
EP1567154A4 (de) *	2002-11-06	2006-05-31	Celgene Corp	Verfahren undzusammensetzungen mit selektiven cytokin-hemmenden arzneimitteln zurbehandlung und versorgung von krebs und anderen erkrankungen
BR0316256A (pt) *	2002-11-18	2005-10-04	Celgene Corp	Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
WO2004045597A1 (en) *	2002-11-18	2004-06-03	Celgene Corporation	Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CA2511843C (en)	2002-12-30	2012-04-24	Celgene Corporation	Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
KR100831545B1 (ko) *	2003-03-06	2008-05-21	셀진 코포레이션	중추 신경계 장애의 치료 또는 관리를 위한 선택적사이토카인 억제 약물의 사용 방법 및 그를 포함하는조성물
US20040175382A1 (en) *	2003-03-06	2004-09-09	Schafer Peter H.	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN100427465C (zh) *	2003-03-12	2008-10-22	细胞基因公司	N-烷基-异羟肟酸-异吲哚基化合物及其药物用途
ZA200507284B (en) *	2003-03-12	2007-03-28	Celgene Corp	7-amino-isoindolyl compounds and their pharmaceutical uses
DE602004032522D1 (de) *	2003-03-12	2011-06-16	Celgene Corp	Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
EP1613269B1 (de)	2003-04-04	2015-02-25	Incyte Corporation	Zusammensetzungen, verfahren und kits in zusammenhang mit her-2 spaltung
US7320992B2 (en) *	2003-08-25	2008-01-22	Amgen Inc.	Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
JP2007524656A (ja) *	2003-10-23	2007-08-30	セルジーン・コーポレーション	疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法
US20050142104A1 (en) *	2003-11-06	2005-06-30	Zeldis Jerome B.	Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
CA2563207A1 (en) *	2004-04-14	2005-11-24	Celgene Corporation	Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
BRPI0510166A (pt) *	2004-04-23	2007-10-02	Celgene Corp	método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
MXPA06012701A (es) *	2004-05-05	2007-02-14	Celgene Corp	Metodo de utilizacion y composiciones que comprenden farmacos inhibidores de citocina selectivos para el tratamiento y manejo de enfermedades mieloproliferativas.
AU2004319815A1 (en) *	2004-05-05	2005-12-01	Celgene Corporation	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2006004191A1 (en) *	2004-07-05	2006-01-12	Astellas Pharma Inc.	Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
US7244759B2 (en) *	2004-07-28	2007-07-17	Celgene Corporation	Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) *	2004-09-03	2007-08-16	Zeldis Jerome B	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
BRPI0514857A (pt) *	2004-09-03	2008-05-06	Celgene Corp	composto ou um sal, solvato ou hidrato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para inibir a angiogênese, para inibir ou reduzir a polimerização da tubulina ou a estabilidade da tubulina em uma célula, para inibir a atividade de pde4 em uma célula, para inibir atividade do fator-alfa de necrose de tumor (tnf-alfa) em uma célula, para tratar ou melhorar um distúrbio inflamatório, para tratar ou melhorar cáncer, para inibir a proliferação de célula cancerosa, para marcar, bloquear ou destruir a função de vasculatura tumoral, para marcar, bloquear ou destruir o endotélio de vasos tumor, para marcar, bloquear ou destruir a função de vasculatura tumoral e inibir a angiogênese em um tumor e para tratar ou melhorar um distúrbio do sistema nervoso central
JP2008518924A (ja) *	2004-10-28	2008-06-05	セルジーン・コーポレーション	中枢神経系損傷の治療及び管理のためのｐｄｅ４モジュレータを使用する方法及び組成物
JP2008523102A (ja) *	2004-12-13	2008-07-03	セルジーン・コーポレーション	Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用
US20070155791A1 (en) *	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
EP2268279A1 (de) *	2008-03-24	2011-01-05	Celgene Corporation	Behandlung von psoriasis oder psoriatischer arthritis mit cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl}-3-oxoisoindolin-4-yl}carbonsäureamid
EP2344479B1 (de) *	2008-09-23	2015-04-08	Georgetown University	1,2-benzisothiazolinon- und isoindolinonderivate
US8563580B2 (en) *	2008-09-23	2013-10-22	Georgetown University	Flavivirus inhibitors and methods for their use
CN102387798A (zh)	2009-02-10	2012-03-21	细胞基因公司	供治疗、预防和控制结核病的pde4调节剂的使用方法及包含其的组合物
CN108059635B (zh) *	2009-05-14	2021-10-01	天津合美医药科技有限公司	噻吩衍生物
US8124646B2 (en)	2009-06-18	2012-02-28	Concert Pharmaceuticals, Inc.	Substituted isoindoline-1,3-dione derivatives
AU2010303243B2 (en) *	2009-10-09	2014-08-28	Celgene Corporation	Processes for the preparation of 2-(1-phenylethyl) isoindolin-1-one compounds
AU2010333767A1 (en) *	2009-12-22	2012-07-05	Celgene Corporation	(Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
JP5937060B2 (ja)	2010-04-07	2016-06-22	セルジーンコーポレイション	呼吸器ウイルス感染症の治療方法
JP2013531499A (ja)	2010-06-15	2013-08-08	セルジーンコーポレイション	乾癬の治療のためのバイオマーカー
MX347928B (es) *	2011-01-10	2017-05-19	Celgene Corp	Derivados de fenetilsulfona isoindolina y su uso.
MX2013007959A (es) *	2011-01-10	2013-12-06	Celgene Corp	Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico.
WO2012097116A2 (en)	2011-01-14	2012-07-19	Celgene Corporation	Isotopologues of isoindole derivatives
JP2014511393A (ja) *	2011-03-07	2014-05-15	セルジーンコーポレイション	イソインドリン化合物を用いた疾患の治療方法
CA2845551C (en)	2011-08-16	2020-06-09	Georgetown University	Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
JP2014526508A (ja) *	2011-09-14	2014-10-06	セルジーンコーポレイション	シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの製剤
US8981117B2 (en)	2012-09-14	2015-03-17	Celgene Corporation	Processes for the preparation of isoindole compounds and isotopologues thereof
US20170087129A1 (en)	2014-05-16	2017-03-30	Celgene Corporation	Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
JP6687550B2 (ja)	2014-06-23	2020-04-22	セルジーンコーポレイション	肝疾患又は肝機能異常を治療するためのアプレミラスト
BR112017019850A2 (pt) *	2015-03-19	2018-06-05	Cipla Ltd	?processo melhorado para a preparação de apremilast?
US10682336B2 (en)	2015-10-21	2020-06-16	Amgen Inc.	PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
HU231259B1 (hu)	2016-02-04	2022-06-28	Egyt Gyogyszervegyeszeti Gyar	Eljárás pomalidomide elõállítására
JP7029444B2 (ja) *	2016-08-22	2022-04-07	メッドシャインディスカバリーインコーポレイテッド	Ｐｄｅ４阻害剤
CN107698484B (zh) *	2017-11-13	2020-05-19	广东中科药物研究有限公司	一种来那度胺的衍生物的制备方法与应用
WO2019142124A1 (en)	2018-01-17	2019-07-25	Cadila Healthcare Limited	Pharmaceutical compositions for treatment of vitiligo
JP7535995B2 (ja)	2018-04-17	2024-08-19	天津合美医▲薬▼科技有限公司	イソインドール誘導体
CN110746376B (zh) *	2018-07-22	2024-04-30	上海星叶医药科技有限公司	苯并异硒唑酮胺类化合物及其制备方法和用途
CN110003084B (zh) *	2019-03-15	2022-08-02	华南师范大学	一种同时具有力致发光和聚集诱导发光特性的有机圆偏振发光材料及其制备方法与应用
CN111170925B (zh) *	2020-01-09	2023-01-17	常州大学	作为pde2/4双重抑制剂的邻苯二甲酰亚胺类化合物及其制备方法
CA3201965A1 (en) *	2020-12-14	2022-06-23	Kyle W.H. Chan	Pde4 degraders, pharmaceutical compositions, and therapeutic applications
AU2022240650B2 (en) *	2021-03-15	2025-01-30	Shenzhen Forward Pharmaceuticals Co., Limited	Estrogen receptor antagonist
CN114790164B (zh)	2021-08-13	2022-12-27	苏州璞正医药有限公司	一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
CN116354857B (zh) *	2023-03-01	2025-01-21	中国人民解放军海军军医大学	一种β-氨基砜及其衍生物的制备方法
CN120000646A (zh) *	2023-11-14	2025-05-16	天津合美医药科技有限公司	干燥综合征的预防或治疗
WO2025103426A1 (zh) *	2023-11-14	2025-05-22	赣州和美药业股份有限公司	白塞综合征的治疗

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4173652A (en)	1976-12-18	1979-11-06	Akzona Incorporated	Pharmaceutical hydroxamic acid compositions and uses thereof
SE434638B (sv)	1980-06-06	1984-08-06	Lekemedelsfabriken Medica Ab	Nya terapeutiska verdefulla taurinderivat och deras framstellning
US4820828A (en)	1987-03-04	1989-04-11	Ortho Pharmaceutical Corporation	Cinnamohydroxamic acids
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
US5463063A (en) *	1993-07-02	1995-10-31	Celgene Corporation	Ring closure of N-phthaloylglutamines
US5605914A (en)	1993-07-02	1997-02-25	Celgene Corporation	Imides
US5703098A (en)	1994-12-30	1997-12-30	Celgene Corporation	Immunotherapeutic imides/amides
US5801195A (en)	1994-12-30	1998-09-01	Celgene Corporation	Immunotherapeutic aryl amides
US6429221B1 (en) *	1994-12-30	2002-08-06	Celgene Corporation	Substituted imides
CN1090614C (zh)	1995-07-26	2002-09-11	辉瑞大药厂	N－(芳酰基)甘氨酸异羟肟酸衍生物及相关化合物
US5728844A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
US5728845A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic nitriles
US5658940A (en)	1995-10-06	1997-08-19	Celgene Corporation	Succinimide and maleimide cytokine inhibitors
ES2217386T3 (es)	1996-01-02	2004-11-01	Aventis Pharmaceuticals Inc.	Compuestos de acido(aril, heteroaril, arilmetil o heteroarilmetil) hidroxamico sustituido.
WO1998005635A1 (en) *	1996-08-07	1998-02-12	Darwin Discovery Limited	Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
ES2315435T3 (es)	1996-08-12	2009-04-01	Celgene Corporation	Nuevos agentes inmunoterapeuticos y su uso para la reduccion de los niveles de citoquinas.
US6214857B1 (en) *	1997-07-31	2001-04-10	Celgene Corporation	Substituted alkanohydroxamic acids and method of reducing TNFα levels
US6020358A (en)	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels

2000
- 2000-11-08 US US09/708,199 patent/US6667316B1/en not_active Expired - Lifetime
- 2000-11-09 EP EP10176390A patent/EP2255801B1/de not_active Expired - Lifetime
- 2000-11-09 AT AT06009632T patent/ATE506058T1/de not_active IP Right Cessation
- 2000-11-09 WO PCT/US2000/030770 patent/WO2001034606A1/en not_active Ceased
- 2000-11-09 PT PT00977095T patent/PT1228071E/pt unknown
- 2000-11-09 EP EP10176420A patent/EP2263669B1/de not_active Expired - Lifetime
- 2000-11-09 JP JP2001536553A patent/JP5116201B2/ja not_active Expired - Fee Related
- 2000-11-09 ES ES10176420T patent/ES2380574T3/es not_active Expired - Lifetime
- 2000-11-09 EP EP06009632A patent/EP1698334B1/de not_active Expired - Lifetime
- 2000-11-09 HK HK03100819.6A patent/HK1049158A1/zh unknown
- 2000-11-09 EP EP00977095A patent/EP1228071B8/de not_active Expired - Lifetime
- 2000-11-09 CN CNB00818254XA patent/CN1325497C/zh not_active Expired - Fee Related
- 2000-11-09 AT AT10176390T patent/ATE544451T1/de active
- 2000-11-09 AU AU14780/01A patent/AU782409B2/en not_active Ceased
- 2000-11-09 DE DE60034139T patent/DE60034139T2/de not_active Expired - Lifetime
- 2000-11-09 DK DK10176420.7T patent/DK2263669T3/da active
- 2000-11-09 CA CA002392081A patent/CA2392081C/en not_active Expired - Fee Related
- 2000-11-09 SI SI200030951T patent/SI1228071T1/sl unknown
- 2000-11-09 PT PT10176420T patent/PT2263669E/pt unknown
- 2000-11-09 ES ES00977095T patent/ES2282147T3/es not_active Expired - Lifetime
- 2000-11-09 AT AT10176420T patent/ATE544452T1/de active
- 2000-11-09 AT AT00977095T patent/ATE357913T1/de active
- 2000-11-09 ES ES10176390T patent/ES2381174T3/es not_active Expired - Lifetime
- 2000-11-09 ES ES06009632T patent/ES2363933T3/es not_active Expired - Lifetime
- 2000-11-09 NZ NZ519459A patent/NZ519459A/en not_active IP Right Cessation
- 2000-11-09 DK DK00977095T patent/DK1228071T3/da active
- 2000-11-09 MX MXPA02004793A patent/MXPA02004793A/es active IP Right Grant
2002
- 2002-05-08 NO NO20022223A patent/NO323633B1/no not_active IP Right Cessation
- 2002-05-10 FI FI20020892A patent/FI119931B/fi not_active IP Right Cessation
2005
- 2005-07-07 AU AU2005202964A patent/AU2005202964B2/en not_active Ceased
2007
- 2007-03-21 NO NO20071490A patent/NO336210B1/no not_active IP Right Cessation
- 2007-04-05 CY CY20071100487T patent/CY1107610T1/el unknown
2012
- 2012-04-26 CY CY20121100399T patent/CY1112707T1/el unknown

Also Published As

Publication number	Publication date
NO323633B1 (no)	2007-06-18
NO20022223D0 (no)	2002-05-08
DK2263669T3 (da)	2012-04-23
FI20020892A0 (fi)	2002-05-10
HK1049158A1 (zh)	2003-05-02
NO20022223L (no)	2002-07-08
EP2255801B1 (de)	2012-02-08
NZ519459A (en)	2003-11-28
JP2004500346A (ja)	2004-01-08
ATE544451T1 (de)	2012-02-15
DE60034139T2 (de)	2007-12-06
ES2282147T3 (es)	2007-10-16
CN1325497C (zh)	2007-07-11
AU2005202964B2 (en)	2007-11-22
AU782409B2 (en)	2005-07-28
EP2255801A1 (de)	2010-12-01
US6667316B1 (en)	2003-12-23
JP5116201B2 (ja)	2013-01-09
DE60034139D1 (de)	2007-05-10
PT2263669E (pt)	2012-04-23
WO2001034606A1 (en)	2001-05-17
CA2392081C (en)	2010-01-05
ES2380574T3 (es)	2012-05-16
EP1228071A1 (de)	2002-08-07
ES2363933T3 (es)	2011-08-19
NO336210B1 (no)	2015-06-15
EP1698334A1 (de)	2006-09-06
EP1228071B1 (de)	2007-03-28
EP1698334B1 (de)	2011-04-20
FI119931B (fi)	2009-05-15
HK1053467A1 (en)	2003-10-24
EP1228071A4 (de)	2002-12-04
ES2381174T3 (es)	2012-05-23
EP2263669B1 (de)	2012-02-08
CA2392081A1 (en)	2001-05-17
PT1228071E (pt)	2007-05-31
ATE357913T1 (de)	2007-04-15
MXPA02004793A (es)	2003-10-14
EP1228071B8 (de)	2012-02-29
CN1420889A (zh)	2003-05-28
CY1107610T1 (el)	2013-03-13
AU2005202964A1 (en)	2005-08-11
ATE506058T1 (de)	2011-05-15
FI20020892L (fi)	2002-06-20
SI1228071T1 (sl)	2007-08-31
AU1478001A (en)	2001-06-06
CY1112707T1 (el)	2016-02-10
DK1228071T3 (da)	2007-08-06
EP2263669A1 (de)	2010-12-22
NO20071490L (no)	2002-07-08

Publication	Publication Date	Title
ATE506058T1 (de)	2011-05-15	Pharmazeutisch aktive isoindolin-derivate
CY1123084T1 (el)	2021-10-29	Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
CO5580776A2 (es)	2005-11-30	Formulacion farmaceutica estable en solucion de oxaliplatino
DE60045168D1 (de)	2010-12-09	Kombinationspräparate enthaltend (E)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r,5s)-3,5-dihydroxyhept-6-enoic Säure
ES2172143T3 (es)	2002-09-16	Combinaciones de productos activos fungicidas.
DK1206261T3 (da)	2006-07-03	Farmaceutiske præparater, der omfatter clavuansyre eller derivater deraf, til behandlingen af adfærdsmæssige sygdomme
HRP20000494B1 (en)	2009-02-28	Pharmaceutically active morpholinol
BR0109650A (pt)	2003-04-22	3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
AU2001296865A1 (en)	2002-03-22	(5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
DK0998287T3 (da)	2003-09-01	Anvendelse af levobupivacain
IT1311921B1 (it)	2002-03-20	Composti farmaceutici.
EA200101150A1 (ru)	2002-04-25	Раствор прукалоприда для перорального применения
IT1306706B1 (it)	2001-10-02	Articolatore perfezionato per la realizzazione di modelli in gesso.
RU2000106182A (ru)	2002-01-27	Средство для лечения поражения кожи различной этиологии
ATE222103T1 (de)	2002-08-15	Inklusionskomplexe in waessriger loesung
RU2000104099A (ru)	2001-10-27	Средство для локальной противоревматической терапии
DK1086695T3 (da)	2005-04-25	Antivirale præparater omfattende yohimbin som aktivt princip
ATE302582T1 (de)	2005-09-15	Haartonikum mit l-arginin als wirkstoff
IT1310896B1 (it)	2002-02-27	Articolatore per odontotecnica.
EP1210949A4 (de)	2003-03-19	Mittel mit antiulcus wirkung
IT1311630B1 (it)	2002-03-14	Perfezionamento ad una struttura di vassoio isotermico,particolarmente per la somministrazione delle vivande alle comunita'.
IT1316492B1 (it)	2003-04-22	Accessorio polifunzionale, particolarmente per la cura dell'acquario.
ITBS990062V0 (it)	1999-07-06	Trave composta per solaio.
ES1044422Y (es)	2000-09-01	Foco empotrable perfeccionado.
ES1042364Y (es)	2000-01-16	"pañal perfeccionado".